KRAS-mutant LUAD co-altered by STK11/LKB1 or KEAP1 mutations exhibits a myeloid-dominant, “cold tumor” state with low PD-L1 and inferior responses to PD-(L)1 therapy [90]. Here, STK11 is linked to neoplasm.